End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.4 CNY | +0.43% |
|
+6.91% | -25.89% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 51% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an enterprise value anticipated at 4.47 times the sales for the current fiscal year, the company turns out to be overvalued.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.89% | 4.14B | C- | ||
+6.96% | 101B | A- | ||
+8.29% | 42.63B | A- | ||
-11.09% | 33.5B | B- | ||
+82.32% | 29.77B | A | ||
-11.82% | 16.14B | C | ||
+1.39% | 14.31B | B- | ||
-12.13% | 11.55B | D+ | ||
+176.65% | 10.53B | D | ||
+6.74% | 9.2B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002007 Stock
- Ratings Hualan Biological Engineering Inc.